Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Exploring Kawasaki Disease

Mary Beth Son, MD  |  Issue: April 2014  |  April 2, 2014

Studies have identified certain demographic features of children at high risk for resistance to treatment with immune intravenous globulin (IVIG) with the concomitant risk of coronary artery aneurysms. Risk factors include male sex, age younger than 6 months and older than 9 years, Asian/Pacific Islander race and Hispanic ethnicity, as well as laboratory findings at the time of diagnosis, including leukocytosis, thrombo­cytopenia, hypoalbuminemia, hyponatremia, trans­aminitis and an elevated C-reactive protein.

Risk scores to identify children at risk for IVIG resistance have been constructed and tested in Japanese populations by Kobayashi et al,3 Sano et al4 and Egami et al.5 Unfortunately, these risk scores do not appear to successfully identify North American children at risk for IVIG resistance.6

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Etiology

As mentioned above, the etiology of KD remains unknown. The hallmark symptoms of fever and rash mimic an infectious disease, and discrete seasonal peaks with clustering of cases in geographic areas suggest a transmittable vector.7

Further, the epidemiology of KD is consistent with an infectious agent, because it is highly unusual for two populations to have KD: very young babies who may be protected by maternal antibodies via placental transfer, and adults who have presumably seen multiple infectious agents and are immune. However, an infectious agent has been searched for exhaustively. To date no single culprit has been found.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Other theories of the pathogenesis of KD include the possibility of superantigen activity, because children can present with hypotension if myocarditis is significant and there is erythroderma present. However, studies of toxins made by Staphylococcus aureus and Streptococcus pyogenes acting as superantigens have varied in regard to conclusive evidence of such.

Genome-wide association studies have identified polymorphisms in the ITPKC gene (a T cell regulator),8 in B lymphoid tyrosine kinase9 and in a high-affinity receptor for immunoglobulin G (FCGR2A) in patients with KD.10 The functional single-nucleotide polymorphisms in the ITPKC gene have been associated with IVIG resistance and worse coronary artery outcomes.

An alternative hypothesis for the pathogenesis of KD is that multiple environmental and/or infectious triggers may lead to a stereotyped inflammatory cascade with the characteristic features of KD as a final common pathway.

Evaluation of Suspected Incomplete Kawasaki Disease. Source: Reprinted with permission.<br /><br />
Circulation. 2004;110:2747–2771. ©2004 American Heart Association, Inc.
click for large version
Figure 1: Evaluation of Suspected Incomplete Kawasaki Disease. Source: Reprinted with permission. Circulation. 2004;110:2747–2771. ©2004 American Heart Association, Inc.

Clinical Features & Diagnosis

The diagnosis of KD relies on a case definition (Table 1), because reliable diagnostic testing has not yet been discovered. It should be noted that not all features of KD may be present simultaneously, and a thorough history of the course of the illness is required. All features of KD will resolve, typically within 11–12 days, even in the absence of treatment.

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditions Tagged with:ACR/ARHP Annual Meetingimmune intravenous globulininfliximabJuvenile idiopathic arthritisKawasaki diseasepatient carerheumatologist

Related Articles
    MIA Studio / shutterstock.com

    Kawasaki Guideline Urges Treatment Intensification for Some Patients

    December 16, 2021

    A soon-to-be published guideline from the ACR and the Vasculitis Foundation on Kawasaki disease underscores the importance of early diagnosis and intensified treatment for people with this serious condition.1 Intravenous immunoglobulin (IVIG) remains the treatment mainstay, and prompt, aggressive treatment may be able to reduce the risk of serious complications in some patients. The guideline…

    The Mystery of IVIg

    March 8, 2012

    Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.

    Dr. Kawasaki

    Tomisaku Kawasaki, Pediatrician Who Discovered Disease That Bears His Name, Dies at 95

    June 18, 2020

    Japanese pediatrician Tomisaku Kawasaki, MD, who identified an inflammatory syndrome that affects children, died on June 5 in Tokyo. He was 95. Tenacity & Attention to Detail Born Feb. 7, 1925, in Tokyo, Dr. Kawasaki graduated from medical school at what is now Chiba University in Chiba, Japan, in 1948 and worked as staff pediatrician…

    Thinking Big, Thinking Small

    June 17, 2019

    I would like to tell you a story. Two, actually. I am just returning from the 19th International Vasculitis and ANCA Workshop, which is always a fascinating meeting. In its inception, it was a workshop, in the true sense of the word. Now, we discuss anti-neutrophil cytoplasmic antibody (ANCA) testing as casually as we discuss…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences